You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023248016
Dec 202344011
Jan 20245307
Feb 20245003
Mar 20245208
Apr 20243804
May 20241604
Jun 20243207
Jul 20244405
Aug 20244203
Sep 20244004
Oct 20242806
Nov 20242809
Dec 20242205
Jan 20253206
Feb 2025704
Mar 20250015
Apr 2025002
May 2025004
Jun 2025005
Total7760128